EpiVax, Inc.

Bronze sponsor

EpiVax partners with biologic and vaccine developers to manage immunogenicity risk across the entire product lifecycle. We develop and apply validated in silico tools for T cell epitope identification and characterization, delivering precise insight into sequence-driven immune recognition. These analyses are complemented by modular in vitro assays that assess both innate and T cell-driven immune responses.

In addition to our analytical platforms, our expert consulting supports integrated interpretation of complex datasets and immunogenicity strategy development, helping teams translate results into clear, defensible decisions. Together, these coordinated approaches reduce uncertainty, strengthen risk mitigation, and enable the development of safer, more effective therapies.

For more information, please visit the EpiVax, Inc. website